The company will make money in the new drug factory in the Federal State Virginia and in the expansion of capacity for research and development and the production of cell therapies in Maryland, Massachusetts, California, Indiana and Texas, stands in a statement.
They intend to restore the US supply network for clinical trials and support continuous investment in innovative medications, Hina reports.
Capacity enlargement in the US will help the British-Swedish diva achieve the planned annual income of $ 80 to 2030, which should be coming from the USA, the statement would be stated. In the United States, last year, 40 percent of the total annual revenue achieved.
The American marketplace is worth 635 billion dollars and is the largest in the world. AstraZeneca included him first priority and before returning Donald Trump in the White House in January this year.
At the very beginning of the new term, Trump threatened customs to import medication to encourage domestic production. In the current commercials, the pharmaceutical sector was exempt from such measures.
The US president asks pharmaceutical companies not to import active ingredients or finished products but that medications that sell in the American market to greater measure products in the USA. And their prices should lower the levels that pay other countries according to Trump words.
Executive Director of Astrazenece Pascal Soryot said in the investment announcement that drug prices should increase in other countries to equalize them, as it would have been increased, and their contribution in the research and development costs.
“The United States cannot bear research and development costs for the whole world,” Soryot said.
The announced investment of Astrazenice in the United States has followed the publication of other pharmaceutical companies. Swiss Roche announced in April that $ 50 billion will invest in the US, and similar amounts are planning to spend the Eli Lilly & Co., Johnson & Johnson, Novartis and Sanofi, notes Reuters.
(Vijesti.ba)
